MTN is pleased to announce that the final site for the DELIVER study has started screening.
MTN is pleased to announce that the final site for the DELIVER study (MTN-042) evaluating the safety and acceptability of two different HIV prevention approaches – the monthly dapivirine vaginal ring and Truvada as daily oral PrEP – when used during pregnancy has started screening. The College of Medicine-Johns Hopkins University Research Project in Blantyre, Malawi joins three other sites currently enrolling for DELIVER – the Wits Reproductive Health and HIV Institute Shandukani Research Centre in Johannesburg, South Africa; the Makerere University-Johns Hopkins Research Collaboration in Kampala, Uganda; and the University of Zimbabwe College of Health Sciences Clinical Trials Research Centre, Zengeza.
DELIVER is a first-of-its-kind study of the dapivirine vaginal ring in pregnant women and will also provide much needed information about the safety of Truvada as PrEP in this population. Ultimately, the goal of the DELIVER, in concert with a companion study called B-PROTECTED (MTN-043) in breastfeeding women, is to ensure cisgender women have safe and effective HIV prevention options they can use throughout their lives.